ADDRESS: Street, City, Country
PHONE: +(123) 456 789
E-MAIL: your-email@mail.com
As part of the Jan Vishwas reforms, five provisions of the Clinical Establishments Act, 2010 were rationalised. Read on to know the changes…
imphoenix82
The US Food and Drug Administration (FDA) has approved Pfizer’s IBRANCE (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy as a maintenance treatment for adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer following induction treatment. IBRANCE is an oral inhibitor of […]
imphoenix82
WHO is encouraging all countries to begin newborn screening with priority conditions and gradually expand as healthcare capacity grows.
imphoenix82
The regulator said it had received reports that ART media and related products were being supplied to unregistered facilities, thereby posing risk to patient health and welfare.
imphoenix82
The move follows a public notice issued on February 11, 2026, seeking feedback on the existing exemption list covering 354 medical devices
imphoenix82
The approval of Satri-cel in China marks the first time a CAR-T therapy for a solid tumour has successfully reached the market, offering new hope to patients with advanced gastric cancer.
imphoenix82
China-based Valgen Medtech has announced that its proprietary DragonFly Transcatheter Mitral Valve Repair System has received CE mark approval in the European Union for the treatment of Functional Mitral Regurgitation (FMR). The latest approval follows the device’s EU authorization for Degenerative Mitral Regurgitation (DMR) in April 2025, making DragonFly the first transcatheter mitral valve repair […]
imphoenix82
The EU has cleared Sanofi’s Cenrifki (tolebrutinib) as the first therapy to target disability progression in secondary progressive multiple sclerosis without relapses, while Japan has approved Wayrilz for immune thrombocytopenia (ITP).
imphoenix82
Abu Dhabi DoH and Sanofi have strengthened their partnership to advance vaccine innovation and to jointly explore the development of a Vaccine Innovation Centre in Abu Dhabi.
imphoenix82
CPHI/Hi Korea 2026 is expected to bring together more than 420 companies from over 70 countries.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 8447496924
HealthXploreIndia @2026. All Rights Reserved.
